However, Kim et al (52) reported the treatment of 46 T-cell lymphoma patients using bortezomib combined with the cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy program, including 10 cases of ENKTCL-N, eight cases of angioimmunoblastic T-cell lymphoma, six cases of anaplastic lymphoma kinase-negative anaplastic large cell lymphoma, five cases of cutaneous T-cell lymphoma, one case of hepatorenal T-cell lymphoma and 16 cases of non-independently classified peripheral T-cell lymphoma. Here, ALK is linked to T-cell non-Hodgkin lymphoma.